RCUS Earnings Date: Nov 4, 2026 (Estimated) — Arcus Biosciences, Inc.
NYSE · Healthcare · Biotechnology
Updated
When is RCUS's next earnings date?
Arcus Biosciences, Inc. (RCUS) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.89 on revenue of $7.6M.
How did RCUS do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Arcus Biosciences, Inc. posted EPS of -$0.72 versus the -$0.89 estimate, a beat of 15.3%. Revenue was $41.0M against a $22.0M estimate. The stock's 1-day post-earnings move was +2.3%.
How much does RCUS stock move after earnings?
RCUS beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.7% (up or down) in the day after earnings.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.89 | -0.72 | +15.29% | $41.0M | ✅ Beat | +2.27% | +4.55% | +8.77% |
| 2026-05-05 | Q1 2026 | -0.85 | -1.02 | -20.00% | $17.0M | ❌ Miss | -0.23% | -4.45% | -5.26% |
| 2026-02-25 | Q4 2025 | -1.09 | -0.89 | +18.35% | $33.0M | ✅ Beat | -3.60% | +11.89% | +4.64% |
| 2025-10-28 | Q3 2025 | -1.31 | -1.27 | +3.05% | $26.0M | ✅ Beat | +2.06% | -0.25% | +28.57% |
| 2025-08-06 | Q2 2025 | -1.16 | 0.00 | +100.09% | $160.0M | ✅ Beat | -2.21% | +6.01% | +28.45% |
| 2025-02-25 | Q4 2024 | -1.20 | -1.03 | +14.17% | $36.0M | ✅ Beat | -0.98% | -5.37% | -19.34% |
| 2024-11-06 | Q3 2024 | -1.06 | -1.00 | +5.66% | $48.0M | ✅ Beat | +4.64% | +4.45% | +9.92% |
| 2024-05-08 | Q1 2024 | -0.93 | -0.05 | +94.62% | $145.0M | ✅ Beat | +5.83% | +15.01% | +1.57% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $41.0M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Other Collaboration Revenue | 61.0% | $25.0M | — | $7.0M | $19.0M | $8.0M | — |
| License And Development Services | 39.0% | $16.0M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.